Correction to: The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.

Journal

Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849

Informations de publication

Date de publication:
Mar 2019
Historique:
pubmed: 2 8 2018
medline: 2 8 2018
entrez: 2 8 2018
Statut: ppublish

Résumé

The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), by deoxycytidine kinase.

Identifiants

DOI: 10.1007/s40262-018-0706-x PMID: 30066294 PMC: PMC6828497
pubmed: 30066294
doi: 10.1007/s40262-018-0706-x
pii: 10.1007/s40262-018-0706-x
pmc: PMC6828497
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

401

Commentaires et corrections

Type : ErratumFor

Auteurs

Robert Hermann (R)

Clinical Research Appliance (Cr Appliance), Heinrich-Vingerhut-Weg 3, 63571, Gelnhausen, Germany. robert.hermann@cr-appliance.com.

Mats O Karlsson (MO)

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Ana M Novakovic (AM)

Merck KGaA, Darmstadt, Germany.

Nadia Terranova (N)

Merck Institute for Pharmacometrics, Merck Serono S.A., Switzerland, an Affiliate of Merck KGaA, Darmstadt, Germany.

Markus Fluck (M)

Merck KGaA, Darmstadt, Germany.

Alain Munafo (A)

Merck Institute for Pharmacometrics, Merck Serono S.A., Switzerland, an Affiliate of Merck KGaA, Darmstadt, Germany.

Classifications MeSH